3BH9 image
Entry Detail
PDB ID:
3BH9
Keywords:
Title:
Crystal Structure of RTY Phosphopeptide Bound to Human Class I MHC HLA-A2
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2007-11-28
Release Date:
2008-10-21
Method Details:
Experimental Method:
Resolution:
1.70 Å
R-Value Free:
0.22
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:HLA class I histocompatibility antigen, A-2 alpha chain
Chain IDs:A
Chain Length:275
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Beta-2-microglobulin
Chain IDs:B
Chain Length:100
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:decameric peptide from Protein POF1B
Chain IDs:C
Chain Length:10
Number of Molecules:1
Biological Source:
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
SEP C SER PHOSPHOSERINE
Primary Citation
Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self
Nat.Immunol. 9 1236 1243 (2008)
PMID: 18836451 DOI: 10.1038/ni.1660

Abstact

Protein phosphorylation generates a source of phosphopeptides that are presented by major histocompatibility complex class I molecules and recognized by T cells. As deregulated phosphorylation is a hallmark of malignant transformation, the differential display of phosphopeptides on cancer cells provides an immunological signature of 'transformed self'. Here we demonstrate that phosphorylation can considerably increase peptide binding affinity for HLA-A2. To understand this, we solved crystal structures of four phosphopeptide-HLA-A2 complexes. These identified a novel peptide-binding motif centered on a solvent-exposed phosphate anchor. Our findings indicate that deregulated phosphorylation can create neoantigens by promoting binding to major histocompatibility complex molecules or by affecting the antigenic identity of presented epitopes. These results highlight the potential of phosphopeptides as novel targets for cancer immunotherapy.

Legend

Protein

Chemical

Disease

Primary Citation of related structures